Ultragenyx backs FY24 revenue view $530M-$550M, consensus $536.8M
The Fly

Ultragenyx backs FY24 revenue view $530M-$550M, consensus $536.8M

The company said, “Crysvita revenue to be towards the upper end of the range of $375 million to $400 million. This includes all regions where Ultragenyx (RARE) will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023. Dojolvi revenue to be in the range of $75 million to $80 million Net Cash Used in Operations of around $400 million.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App